Broad-spectrum antiviral activity of 2-beta-D-ribofuranosylselenazole-4-carboxamide, a new antiviral agent
The relative in vitro antiviral activities of three related nucleoside carboxamides, ribavirin (1-beta-D-ribofuranosyl-1,2,4-triazole-3-carboxamide), tiazofurin (2-beta-D-ribofuranosylthiazole-4-carboxamide), and selenazole (2-beta-D-ribofuranosylselenazole-4-carboxamide), were studied against selected DNA and RNA viruses. Although the activity of selenazole against different viruses varied, it was significantly more potent than ribavirin and tiazofurin against all tested representatives of the families Paramyxoviridae (parainfluenza virus type 3, mumps virus, measles virus), Reoviridae (reovirus type 3), Poxviridae (vaccinia virus), Herpes-viridae (herpes simplex virus types 1 and 2), Togaviridae (Venezuelan equine encephalomyelitis virus, yellow fever virus, Japanese encephalitis virus), Bunyaviridae (Rift Valley fever virus, sandfly fever virus [strain Sicilian], Korean hemorrhagic fever virus), Arenaviridae (Pichinde virus), Picornaviridae (coxsackieviruses B1 and B4, echovirus type 6, encephalomyocarditis virus), Adenoviridae (adenovirus type 2), and Rhabdoviridae (vesicular stomatitis virus). The antiviral activity of selenazole was also cell line dependent, being greatest in HeLa, Vero-76, and Vero E6 cells. Selenazole was relatively nontoxic for Vero, Vero-76, Vero E6, and HeLa cells at concentrations of up to 1,000 micrograms/ml. The relative plating efficiency at that concentration was over 90%. The effects of selenazole on viral replication were greatest when this agent was present at the time of viral infection. The removal of selenazole from the medium of infected cells did not reverse the antiviral effect against vaccinia virus, but there was a gradual resumption of viral replication in cells infected with parainfluenza type 3 or herpes simplex virus type 1 (strain KOS). However, the antiviral activity of ribavirin against the same viruses was reversible when the drug was removed.
Top-30
Journals
|
2
4
6
8
10
|
|
|
Antiviral Research
10 publications, 7.25%
|
|
|
Journal of Medicinal Chemistry
5 publications, 3.62%
|
|
|
Tetrahedron Letters
5 publications, 3.62%
|
|
|
Journal of Heterocyclic Chemistry
5 publications, 3.62%
|
|
|
Nucleosides and Nucleotides
5 publications, 3.62%
|
|
|
Antiviral Chemistry and Chemotherapy
4 publications, 2.9%
|
|
|
Tetrahedron
3 publications, 2.17%
|
|
|
Antiviral Therapy
3 publications, 2.17%
|
|
|
Virus Research
3 publications, 2.17%
|
|
|
Chemical Reviews
3 publications, 2.17%
|
|
|
Advances in Virus Research
3 publications, 2.17%
|
|
|
Mayo Clinic Proceedings
2 publications, 1.45%
|
|
|
Viruses
2 publications, 1.45%
|
|
|
Journal of Labelled Compounds and Radiopharmaceuticals
2 publications, 1.45%
|
|
|
Helvetica Chimica Acta
2 publications, 1.45%
|
|
|
European Journal of Organic Chemistry
2 publications, 1.45%
|
|
|
Journal of Organic Chemistry
2 publications, 1.45%
|
|
|
Organic Letters
2 publications, 1.45%
|
|
|
Organic and Biomolecular Chemistry
2 publications, 1.45%
|
|
|
New Journal of Chemistry
2 publications, 1.45%
|
|
|
Journal of Infectious Diseases
2 publications, 1.45%
|
|
|
Journal of Virology
2 publications, 1.45%
|
|
|
Antimicrobial Agents and Chemotherapy
2 publications, 1.45%
|
|
|
Reference Series in Phytochemistry
2 publications, 1.45%
|
|
|
Seminars in Avian and Exotic Pet Medicine
1 publication, 0.72%
|
|
|
Journal of Virological Methods
1 publication, 0.72%
|
|
|
Microbes and Infection
1 publication, 0.72%
|
|
|
Future Virology
1 publication, 0.72%
|
|
|
Viral Immunology
1 publication, 0.72%
|
|
|
2
4
6
8
10
|
Publishers
|
5
10
15
20
25
30
35
40
45
|
|
|
Elsevier
45 publications, 32.61%
|
|
|
Wiley
19 publications, 13.77%
|
|
|
Taylor & Francis
14 publications, 10.14%
|
|
|
American Chemical Society (ACS)
12 publications, 8.7%
|
|
|
SAGE
8 publications, 5.8%
|
|
|
MDPI
6 publications, 4.35%
|
|
|
Royal Society of Chemistry (RSC)
6 publications, 4.35%
|
|
|
Springer Nature
6 publications, 4.35%
|
|
|
American Society for Microbiology
5 publications, 3.62%
|
|
|
Public Library of Science (PLoS)
2 publications, 1.45%
|
|
|
Oxford University Press
2 publications, 1.45%
|
|
|
Mary Ann Liebert
1 publication, 0.72%
|
|
|
Microbiology Society
1 publication, 0.72%
|
|
|
Pharmaceutical Society of Japan
1 publication, 0.72%
|
|
|
Autonomous Non-profit Organization Editorial Board of the journal Uspekhi Khimii
1 publication, 0.72%
|
|
|
American Diabetes Association
1 publication, 0.72%
|
|
|
Pleiades Publishing
1 publication, 0.72%
|
|
|
5
10
15
20
25
30
35
40
45
|
- We do not take into account publications without a DOI.
- Statistics recalculated weekly.